Membranous Nephropathy Market Set to Grow Substantially Through 2032, DelveInsight Projects | Shanghai Jiaolian Drug R&D, Cerium Pharma, BeiGene, Hoffmann-La Roche, Reistone Biopharma, SynAct Pharma

The Key Membranous Nephropathy Companies in the market inclue - argenx, Tenet Medicines, Mario Negri Institute for Pharmacological, Beijing Mabworks Biotech, Shanghai Jiaolian Drug R&D, Cerium Pharmaceuticals, BeiGene, Hoffmann-La Roche, Reistone Biopharma, SynAct Pharma, Alpine Immune Sciences, Walden Biosciences, Hansa Biopharma AB, and others.

DelveInsight's "Membranous Nephropathy Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Membranous Nephropathy, historical and forecasted epidemiology as well as the Membranous Nephropathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Membranous Nephropathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Membranous Nephropathy Market Forecast [https://www.delveinsight.com/sample-request/membranous-nephropathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Membranous Nephropathy Market Report:

*
The Membranous Nephropathy market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

*
In February 2025, Genentech, a subsidiary of Roche, has submitted positive Phase III data to the U.S. Food and Drug Administration (FDA) as it seeks to enter the lucrative lupus market with its CD20-targeting drug, Gazyva (obinutuzumab). Additionally, the company is investigating Gazyva for other autoimmune conditions, including systemic lupus erythematosus (SLE), childhood-onset idiopathic nephrotic syndrome, membranous nephropathy, and pediatric lupus nephritis.

*
In 2023, idiopathic membranous nephropathy (IMN) accounted for about 80% of membranous nephropathy cases, while secondary cases comprised nearly 20% in the US.

*
In 2023, the number of people in the United States with idiopathic membranous nephropathy was approximately 29,000.

*
In the EU4 and the UK, PLA2R antigens were identified in about 18,000 IMN patients, while THSD7A antigens were found in around 1,000 patients.

*
In a study conducted by Storrar et al. (2022), 178 patients with primary membranous nephropathy were monitored over two decades. The study found that 134 patients (75.3%) achieved remission, either spontaneously in 60 patients (33.7%) or after immunosuppressive treatment in 74 patients (41.6%). Among those in remission, 57 patients (42.5%) experienced a relapse. Additionally, 10.1% of the patients progressed to renal replacement therapy, and the mortality rate was 29.8%.

*
According to a study by Alsharhan and Beck (2020), autoantibodies to PLA2R are believed to be the cause of primary membranous nephropathy (MN) in up to 80% of patients. Additionally, autoantibodies against THSD7A are responsible for 1-3% of MN cases in Western countries.

*
Key Membranous Nephropathy Companies: argenx, Tenet Medicines, Mario Negri Institute for Pharmacological, Beijing Mabworks Biotech, Shanghai Jiaolian Drug R&D, Cerium Pharmaceuticals, BeiGene, Hoffmann-La Roche, Reistone Biopharma, SynAct Pharma, Alpine Immune Sciences, Walden Biosciences, Hansa Biopharma AB, and others

*
Key Membranous Nephropathy Therapies: efgartigimod IV, VB119, MOR202, MIL62, B007, SNP-ACTH (1-39) Gel, Zanubrutinib, Obinutuzumab, SHR1459, AP1189, povetacicept, WAL0921, Imlifidase, and others

*
The Membranous Nephropathy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Membranous Nephropathy pipeline products will significantly revolutionize the Membranous Nephropathy market dynamics.

Membranous Nephropathy Overview

Membranous Nephropathy is a chronic kidney disorder where the body's immune system attacks the membranes in the glomeruli - the tiny filtering units in the kidneys. This leads to thickening of the glomerular basement membrane, causing protein to leak into the urine (proteinuria). It is a common cause of nephrotic syndrome in adults. The condition can be primary (idiopathic) or secondary to other diseases like lupus, infections, cancer, or use of certain medications. Symptoms include swelling (especially in the legs), fatigue, and foamy urine. Treatment depends on the severity and underlying cause, ranging from observation to immunosuppressive therapy.

Get a Free sample for the Membranous Nephropathy Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/membranous-nephropathy-market [https://www.delveinsight.com/report-store/membranous-nephropathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Membranous Nephropathy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Membranous Nephropathy Epidemiology Segmentation:

The Membranous Nephropathy market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

*
Prevalent Cases of Membranous Nephropathy in the 7MM

*
Prevalent Cases of Membranous Nephropathy by Types in the 7MM

*
Prevalent Cases of Idiopathic Membranous Nephropathy by Antigens in the 7MM

*
Treated Cases of Membranous Nephropathy in the 7MM

Download the report to understand which factors are driving Membranous Nephropathy epidemiology trends @ Membranous Nephropathy Epidemiology Forecast [https://www.delveinsight.com/sample-request/membranous-nephropathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Membranous Nephropathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Membranous Nephropathy market or expected to get launched during the study period. The analysis covers Membranous Nephropathy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Membranous Nephropathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Membranous Nephropathy Therapies and Key Companies

*
GAZYVA (obinutuzumab): Hoffmann-La Roche

*
MOR202 (felzartamab): MorphoSys/HI-Bio

*
efgartigimod IV: argenx

*
VB119: Tenet Medicines

*
MOR202: Mario Negri Institute for Pharmacological

*
MIL62: Beijing Mabworks Biotech

*
B007: Shanghai Jiaolian Drug R&D

*
SNP-ACTH (1-39) Gel: Cerium Pharmaceuticals

*
Zanubrutinib: BeiGene

*
Obinutuzumab: Hoffmann-La Roche

*
SHR1459: Reistone Biopharma

*
AP1189: SynAct Pharma

*
povetacicept: Alpine Immune Sciences

*
WAL0921: Walden Biosciences

*
Imlifidase: Hansa Biopharma AB

Discover more about therapies set to grab major Membranous Nephropathy market share @ Membranous Nephropathy Treatment Landscape [https://www.delveinsight.com/sample-request/membranous-nephropathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Membranous Nephropathy Market Strengths

*
The availability of assays for PLA2R antibodies has induced a dramatic change of the diagnostic strategy, owing to the very high specificity of anti-PLA2R antibody for the diagnosis of MN.

*
With better efficacy results, and proteinuria reduction observed in six months after therapy, MOR202 (felzartamab) is expected to emerge as a strong therapeutic candidate and generate decent market share.

Membranous Nephropathy Market Opportunities

*
Absence of marketed therapy in treatment space along with increasing patient pool paves the way for pharma players to come up with efficacious and cost effective treatment options

*
High rate of progression and remission in patients with MN presents pharmaceutical companies with an opportunity to develop therapies to overcome the shortcomings and grab a highly untapped market.

Scope of the Membranous Nephropathy Market Report

*
Study Period: 2019-2032

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Membranous Nephropathy Companies: argenx, Tenet Medicines, Mario Negri Institute for Pharmacological, Beijing Mabworks Biotech, Shanghai Jiaolian Drug R&D, Cerium Pharmaceuticals, BeiGene, Hoffmann-La Roche, Reistone Biopharma, SynAct Pharma, Alpine Immune Sciences, Walden Biosciences, Hansa Biopharma AB, and others

*
Key Membranous Nephropathy Therapies: efgartigimod IV, VB119, MOR202, MIL62, B007, SNP-ACTH (1-39) Gel, Zanubrutinib, Obinutuzumab, SHR1459, AP1189, povetacicept, WAL0921, Imlifidase, and others

*
Membranous Nephropathy Therapeutic Assessment: Membranous Nephropathy current marketed and Membranous Nephropathy emerging therapies

*
Membranous Nephropathy Market Dynamics: Membranous Nephropathy market drivers and Membranous Nephropathy market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Membranous Nephropathy Unmet Needs, KOL's views, Analyst's views, Membranous Nephropathy Market Access and Reimbursement

To know more about Membranous Nephropathy companies working in the treatment market, visit @ Membranous Nephropathy Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/membranous-nephropathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Membranous Nephropathy Market Report Introduction

2. Executive Summary for Membranous Nephropathy

3. SWOT analysis of Membranous Nephropathy

4. Membranous Nephropathy Patient Share (%) Overview at a Glance

5. Membranous Nephropathy Market Overview at a Glance

6. Membranous Nephropathy Disease Background and Overview

7. Membranous Nephropathy Epidemiology and Patient Population

8. Country-Specific Patient Population of Membranous Nephropathy

9. Membranous Nephropathy Current Treatment and Medical Practices

10. Membranous Nephropathy Unmet Needs

11. Membranous Nephropathy Emerging Therapies

12. Membranous Nephropathy Market Outlook

13. Country-Wise Membranous Nephropathy Market Analysis (2019-2032)

14. Membranous Nephropathy Market Access and Reimbursement of Therapies

15. Membranous Nephropathy Market Drivers

16. Membranous Nephropathy Market Barriers

17. Membranous Nephropathy Appendix

18. Membranous Nephropathy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=membranous-nephropathy-market-set-to-grow-substantially-through-2032-delveinsight-projects-shanghai-jiaolian-drug-rd-cerium-pharma-beigene-hoffmannla-roche-reistone-biopharma-synact-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.